Everything below concerns Certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
== Evolutionary conservation == SMN is evolutionarily conserved including the Fungi kingdom, though only fungal organisms with a great number of introns have the Smn gene (or the splicing factor spf30 paralogue). Surprisingly, these are filamentous fungus which have mycelia, so suggesting analogy to the neuronal axons.
=== Draft and minor leagues === The Boston Red Sox selected Bagwell in the fourth round (110th overall) of the 1989 Major League Baseball draft. Throughout his career, Barry Axelrod served as his agent. For his first professional assignment, the Red Sox appointed Bagwell to the Single-A Winter Haven Red Sox of the Florida State League in 1989, where he batted .310 with two home runs. In 1990, while playing for the Double-A New Britain Red Sox, Bagwell won the Eastern League Most Valuable Player Award. In 136 games with New Britain, he batted .333 with 160 hits, four home runs (HR), 61 runs batted in (RBI), 34 doubles, seven triples, 73 bases on balls (BB or walks), 57 strikeouts (SO), .422 on-base percentage (OBP), .457 slugging percentage (SLG) and .880 on-base plus slugging percentage (OPS). He finished first in the league in hits and doubles, second in batting, OBP and OPS, fourth in walks, fifth in SLG, ninth in runs scored and tenth in RBI. Late in the 1990 season, the Red Sox, who were in search of relief pitching to improve their chances of making the playoffs, contacted the Houston Astros about Larry Andersen. Stan Benjamin, who scouted the New England region for the Astros, recommended that they ask for Bagwell in return. The Astros initially hesitated owing to his sparse home run production, but Benjamin persuaded them, quipping that New Britain's Beehive Field was so large that "Babe Ruth couldn't hit home runs in that ballpark."[a] On August 30, 1990, the Red Sox took the Astros' offer.
== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline
=== Football clubs === In the 1960s, Inter Milan has its greatest period of success known as [La] Grande Inter ("Great Inter"), achieved when Helenio Herrera was their manager. He won seven trophies with the club. In 2004, Ferruccio Mazzola, Inter player during that period, accused him of distributing performance-enhancing drugs, including amphetamines, among the team players, especially the substitute players "who often served as guinea pigs for trying new pills and see if they worked." When he found out that some in the team were spitting them out, he dissolved them in coffee to make sure they were consumed, a practice known as Caffè di Herrera ("Herrera's Coffee"). In 2010, Inter sued Mazzola but lost the case, the court believed him. One of the reasons he spoke up were the serious medical conditions and/or deaths of some of his former members: Giuliano Taccola, then team's captain Armando Picchi (died aged 36 due to cancer), Marcello Giusti, Carlo Tagnin, Mauro Bicicli, Ferdinando Miniussi, Enea Masiero and Pino Longoni. He suspected the drugs to be the cause of their sufferings. in 2015, his brother Sandro, who denied everything at the beginning, admitted that the incidents happened. In the 1970s performance-enhancing drugs were used on a regular basis according to witnesses of that period, mostly in Ajax, Feyenoord and AZ Alkmaar during competitive matches, including the 1970 and 1972 Intercontinental Cups won by the first two cited clubs. Jan Peters recounted drug use before the big games. They seemed to work as he felt energy boosts and euphoria.
A few days later, on December 7, Webb engaged two hobbyists, Edgar Van Horn and Ernest Howatt, to photograph the carcass for posterity. At least two photographs were taken, one of the lateral view and one of the anterior view, showing the apparent arm stumps. The latter also included a man, likely DeWitt Webb himself, for scale. As the images were over-exposed, they were never published. These photographs were for a long time considered lost, and only drawings based on them, made by Alpheus Hyatt Verrill and published in the American Naturalist of April 1897, were known. However, one of the original images, showing the lateral view, was obtained by Gary Mangiacopra in 1994. It is clear that one of Verrill's drawings was based on this photograph. A simplified drawing of this image also appeared in the Hartford Daily Running of February 18, 1897. Around the same time, a certain Mr. Wilson wrote a memorandum to Webb, communicating the results of his observations made after having dug around the corpse. It read:
Sources: en.wikipedia.org
A mass chromatogram is a representation of mass spectrometry data as a chromatogram, where the x-axis represents time and the y-axis represents signal intensity. The source data contains mass information; however, it is not graphically represented in a mass chromatogram in favor of visualizing signal intensity versus time. The most common use of this data representation is when mass spectrometry is used in conjunction with some form of chromatography, such as in liquid chromatography–mass spectrometry or gas chromatography–mass spectrometry. In this case, the x-axis represents retention time, analogous to any other chromatogram. The y-axis represents signal intensity or relative signal intensity. There are many different types of metrics that this intensity may represent, depending on what information is extracted from each mass spectrum.
== In the aquarium == The minimum tank size requirement for the Ember tetras is at least 10 gallons with few live aquarium plants. Ember tetras should be kept in acidic water with a pH near 6.6, and although their native habitat has very soft water, they have adapted quite well to a wide range of hardness (5–17 dGH). The recommended temperature range is 23–29 °C (73–84 °F). Ideally their tank should contain live plants , a darker substrate, and open water for swimming. Ember tetras should be kept in groups of at least 6, though the recommended number is 9–10, in order to promote schooling. They appreciate a heavily planted aquarium ideally with a small area shaded from direct light, and will spend a lot of time swimming through planted areas, which also offer some protection for their fry. Ember tetras will school with other tetras, such as the neon tetra, but may become stressed by the presence of significantly larger fish. These fish swim at the middle level of the aquarium, and they do not feed from the bottom of the tank. Therefore, it is recommended that they are kept with other bottom dwelling fish (such as pygmy corydoras) so that leftover food is then eaten up off the substrate and not left to waste. Ember tetras can be fed a variety of foods, including flake, frozen, and freeze dried food. Small live foods like worms and brine shrimp are also recommended, as they bring out the fish's colors. In a well maintained heavily planted aquarium, ember tetras have been known to live ten years or more.
=== Automated insulin delivery === Tandem introduced Basal-IQ in 2018. The feature used predicted CGM values to suspend insulin delivery when glucose was expected to become low and resumed delivery when values recovered. Control-IQ is a hybrid closed-loop system that uses CGM readings and a model-predictive algorithm to increase, decrease or suspend basal insulin and to deliver automatic correction boluses. Users still program personal therapy settings and normally announce meals. The FDA authorized Control-IQ through the De Novo pathway in December 2019, creating a regulatory category for interoperable automated glycemic controllers. Tandem launched it in the United States in January 2020 as a software update for compatible t:slim X2 pumps. A revised version, Control-IQ+, broadened supported therapy settings and was cleared in 2025 for adults with type 2 diabetes who require insulin. In the United States, Control-IQ+ is used on both the t:slim X2 and Mobi platforms.
After a strong pre-season, Melksham had strong form during the 2012 NAB Cup, which led to former Essendon player and The Age journalist, Matthew Lloyd naming Melksham as one of the players who would have a breakout season. After the club had an outstanding start to the season where the team won eight out of nine matches, with the only loss being one point to Collingwood in the Anzac Day clash; hype surrounding the club was immense with 1987 premiership coach, Robert Walls denoting the club could win a premiership, indicating the improvement of the players, especially Melksham, was one of the reasons for a potential flag. Garry Lyon also noted the improvement of Melksham as one of the reasons for Essendon's strong start to the season, along with The Age journalist, Martin Flanagan, praising Melksham and his contribution to the club's fortunes. After round nine, the club lost ten of the final thirteen matches, including the final seven to finish outside of the top eight; the decline in the teams' performance saw Melksham's form dip as well, with The Age journalist, Rohan Connolly stating Melksham's development had "stalled". Despite being one of two players to play every match during the season, he failed to finish inside the top ten in the club best and fairest.
Public Health Emergency Preparedness initiatives are managed by the CDC via the Office of Public Health Preparedness and Response. Funds aim to support communities in preparing for public health emergencies, including pandemic influenza. Also managed by the CDC, the Strategic National Stockpile (SNS) consists of bulk quantities of medicines and supplies for use during such emergencies. Antiviral stockpiles prepare for shortages of antiviral medications in cases of public health emergencies. During the H1N1 pandemic in 2009–2010, guidelines for SNS use by local health departments was unclear, revealing gaps in antiviral planning. For example, local health departments that received antivirals from the SNS did not have transparent guidance on the use of the treatments. The gap made it difficult to create plans and policies for their use and future availabilities, causing delays in treatment.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.